MLICM
KLRS

Metropolitan Life Insurance Company (MetLife)’s Kalaris Therapeutics KLRS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-135
Closed -$6.66K – 2395
2023
Q3 		$6.66K Buy
135
+59
+78% +$4.02K ﹤0.01% 2367
2023
Q2 		$5.92K Buy
76
+56
+280% +$5.32K ﹤0.01% 2446
2023
Q1 		$1.84K Sell
20
-62
-76% -$7.9K ﹤0.01% 2302
2022
Q4 		$9.72K Hold
82
– – ﹤0.01% 2290
2022
Q3 		$15K Buy
+82
New +$12.8K ﹤0.01% 2161
2022
Q2 		– Sell
-86
Closed -$13.4K – 2444
2022
Q1 		$13.4K Sell
86
-267
-76% -$53.3K ﹤0.01% 2225
2021
Q4 		$105K Sell
353
-36
-9% -$16.7K ﹤0.01% 2450
2021
Q3 		$224K Sell
389
-34
-8% -$15.7K ﹤0.01% 1985
2021
Q2 		$192K Buy
423
+44
+12% +$22.7K ﹤0.01% 2168
2021
Q1 		$204K Buy
379
+140
+59% +$118K ﹤0.01% 2007
2020
Q4 		$212K Hold
239
– – ﹤0.01% 1901
2020
Q3 		$151K Buy
+239
New +$163K ﹤0.01% 1953

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s KLRS Position: Q4 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 135 shares — an estimated $6.66K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in KLRS in Q3 2020 and held it in 12 quarters. The position peaked at $224K in Q3 2021. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 135 Kalaris Therapeutics shares in Q4 2023, an estimated $6.66K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 12 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Kalaris Therapeutics position peaked at $224K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2023, filed 14 Feb 2024.